Compare HNNA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNNA | ENTX |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 74.7M |
| IPO Year | N/A | 2015 |
| Metric | HNNA | ENTX |
|---|---|---|
| Price | $9.91 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 15.5K | ★ 172.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.77 | ★ $8.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.43 | $1.00 |
| 52 Week High | $13.19 | $3.22 |
| Indicator | HNNA | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 44.46 |
| Support Level | $9.75 | $1.00 |
| Resistance Level | $10.34 | $2.28 |
| Average True Range (ATR) | 0.27 | 0.14 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 55.32 | 55.08 |
Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.